Twist Bioscience Launches Enzymatic Fragmentation Library Preparation Kit for High Uniformity, High-Yield Amplification, Stre...
25 May 2021 - 10:01PM
Business Wire
-- Efficient Library Preparation Prevents
Wasted Samples --
Twist Bioscience Corporation (Nasdaq: TWST) today launched the
Twist Library Preparation Enzymatic Fragmentation Kit 2.0, a robust
all-in-one solution designed to maximize accuracy and efficiency in
library construction and amplification when conducting
next-generation sequencing (NGS). The kit is optimized for
challenging NGS applications including liquid biopsy, somatic
variant testing and genome-wide association studies. In addition,
the kit excels in preparing samples where the amount of sample
input DNA is either very limited or heavily degraded, as in the
case of many banked oncology samples.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210525005242/en/
Twist Library Preparation Enzymatic
Fragmentation Kit 2.0, a robust all-in-one solution designed to
maximize accuracy and efficiency in library construction and
amplification when conducting next-generation sequencing (NGS) for
targeted applications. (Photo: Business Wire)
“Utilizing robust sample preparation technologies to generate
sequencing libraries sets the stage for high-quality data and
accurate results,” said Emily M. Leproust, Ph.D., CEO and
co-founder of Twist Bioscience. “We’ve introduced this kit to
enable our customers pursuing liquid biopsy, rare variants and
other critical research to generate high-quality data
consistently.”
The Library Preparation Enzymatic Fragmentation Kit 2.0 builds
on Twist’s existing Library Preparation portfolio, giving customers
more options when selecting a solution that works for their unique
application or sample type. Combined with Twist’s industry-leading
target enrichment panels that provide exceptional capture
uniformity to avoid over-sequencing of areas outside the desired
target regions, this new kit integrates a new amplification mix
specifically developed for NGS applications.
“Twist continues to add innovative solutions to its expanding
NGS portfolio to support researchers in a variety of disciplines.
The introduction of these new tools showcases our ongoing
commitment to the research and clinical communities, as we help
them get to answers faster, deliver better outcomes and drive
research forward,” continued Dr. Leproust.
About the Twist Library Preparation Enzymatic Fragmentation
Kit 2.0
The Twist Library Preparation Enzymatic Fragmentation (EF) Kit
2.0 is a customized workflow to efficiently prepare samples that
generate more accurate NGS results. The EF Kit 2.0 enables a
streamlined workflow that combines library preparation steps into a
single-tube reaction which, alongside a low chimera rate and
Twist’s highly uniform target enrichment workflow, translates into
high quality library preparation and NGS data.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including but not limited to the ability of the Twist
Library Preparation Enzymatic Fragmentation Kit 2.0 to enable Twist
customers pursuing liquid biopsy, rare variants and other critical
research to generate high-quality data consistently, to obtain
answers faster, to deliver better outcomes and to drive research
forward, are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; uncertainties
of the retention of a significant customer; risks of third party
claims alleging infringement of patents and proprietary rights or
seeking to invalidate Twist Bioscience’s patents or proprietary
rights; and the risk that Twist Bioscience’s proprietary rights may
be insufficient to protect its technologies. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to Twist Bioscience’s
business in general, see Twist Bioscience’s risk factors set forth
in Twist Bioscience’s Quarterly Report Form 10-Q filed with the
Securities and Exchange Commission on May 7, 2021 and subsequent
filings with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Twist
Bioscience specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210525005242/en/
Angela Bitting 925- 202-6211 abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024